Nanoparticulated heat-stable (STa) and heat-labile B subunit (LTB) recombinant toxin improves vaccine protection against enterotoxigenic Escherichia coli challenge in mouse

Journal of Bioscience and Bioengineering

Volumn 115, Issue 2, 2013, Pages 147-153

  Deng, Guangcun ^a,b   Zeng, Jin ^a,b   Jian, Minjie ^a,b   Liu, Wenmiao ^a,b   Zhang, Zhong ^a,b   Liu, Xiaoming ^a,b   Wang, Yujiong ^a,b  

^a Key Lab of the Ministry of Education for the Conservation   (Japan)

^b Ningxia University ^*  (Japan)

Author keywords

Enterotoxigenic Escherichia coli; Heat labile enterotoxin; Heat stable enterotoxin; Nanoparticle; Vaccine

Indexed keywords

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTRAPMENT EFFICIENCY; FUSION PROTEINS; HEAT-LABILE ENTEROTOXIN; HEAT-STABLE ENTEROTOXIN; IMMUNOGENICITY; LONG LASTING; NANO PARTICULATES; NEUTRALIZING ANTIBODIES; SIZE RANGES; SMOOTH SPHERE;

AMINO ACIDS; ANTIBODIES; ESCHERICHIA COLI; GENETIC ENGINEERING; MAMMALS; NANOPARTICLES; VACCINES;

DISEASES;

ESCHERICHIA COLI ENTEROTOXIN; HEAT LABILE B SUBUNIT ENTERTOXIN; HEAT STABLE ENTEROTOXIN; HYBRID PROTEIN; NANOCARRIER; NANOPARTICLE; NANOVACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; DRUG SYNTHESIS; ENTEROTOXIGENIC ESCHERICHIA COLI; GENETIC ENGINEERING; IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INTESTINE MUCOSA; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; SERUM; VACCINATION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; BACTERIAL TOXINS; BACTERIAL VACCINES; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; GELATIN; HOT TEMPERATURE; MALE; MICE; NANOPARTICLES; PROTEIN STABILITY; RECOMBINANT PROTEINS;

ANIMALIA; ESCHERICHIA COLI; MUS;

EID: 84871929588     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2012.09.009     Document Type: Article

References (48)

1. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 1998, 11:142-201.
2. Shah N., DuPont H.L., Ramsey D.J. Global etiology of travelers diarrhea: systematic review from 1973 to the present. Am. J. Trop. Med. Hyg. 2009, 80:609-614.
3. Qadri F., Svennerholm A.-M., Faruque A.S.G., Sack R.B. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev. 2005, 18:465-483.
4. Robins-Browne R.M., Hartland E.L. Escherichia coli as a cause of diarrhea. J. Gastroenterol. Hepatol. 2002, 17:467-475.
5. Nagy B., Fekete P. Enterotoxigenic Escherichia coli (ETEC) in farm animals. Vet. Res. 1999, 30:259-284.
6. Žutić J., AŠanin J., MiŠić D., Jakić-Dimić D., Milić N., AŠanin R., Stojanović D., Žutić M. Isolation of ETEC strains from piglets with diarrhea in the neonatal period and their typization based on somatic and fimbrial antigens. Acta Vet. 2010, 60:497-506.
7. Nicklasson M., Sjoling A., Lebens M., Tobias J., Janzon A., Brive L., Svennerholm A.M. Mutations in the periplasmic chaperone leading to loss of surface expression of the colonization factor CS6 in enterotoxigenic Escherichia coli (ETEC) clinical isolates. Microb. Pathog. 2008, 44:246-254.
8. Weiglmeier P.R., Ràsch P., Berkner H. Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C. Toxins 2010, 2:2213-2229.
9. Walker R.I. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 2005, 23:3369-3385.
10. Steffen R., Castelli F., Dieter Nothdurft H., Rombo L., Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 2005, 12:102-107.
11. Klipstein F.A., Engert R.F., Houghten R.A. Immunisation of volunteers with a synthetic peptide vaccine for enterotoxigenic Escherichia coli. Lancet 1986, 1:471-472.
12. Wang R., Ma Y. Progress in development of recombinant human enterotoxigenic Escherichia coli vaccine. Chin. J. Biol. 2010, 23:544-548.
13. Taxt A., Aasland R., Sommerfelt H., Nataro J., Puntervoll P. Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect. Immun. 2010, 78:1824-1831.
14. Clements J.D. Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins. Infect. Immun. 1990, 58:1159-1166.
15. Girard M.P., Steele D., Chaignat C.L., Kieny M.P. A review of vaccine research and development: human enteric infections. Vaccine 2006, 24:2732-2750.
16. Houghten R.A., Engert R.F., Ostresh J.M., Hoffman S.R., Klipstein F.A. A completely synthetic toxoid vaccine containing Escherichia coli heat-stable toxin and antigenic determinants of the heat-labile toxin B subunit. Infect. Immun. 1985, 48:735-740.
17. Klipstein F.A., Engert R.F., Houghten R.A. Protection in rabbits immunized with a vaccine of Escherichia coli heat-stable toxin cross-linked to the heat-labile toxin B subunit. Infect. Immun. 1983, 40:888-893.
18. Liu M., Ruan X., Zhang C., Lawson S.R., Knudsen D.E., Nataro J.P., Robertson D.C., Zhang W. Heat-labile- and heat-stable-toxoid fusions (LTR192G-STaP13F) of human enterotoxigenic Escherichia coli elicit neutralizing antitoxin antibodies. Infect. Immun. 2011, 79:4002-4009.
19. Zhang W., Francis D.H. Genetic fusions of heat-labile toxoid (LT) and heat-stable toxin b (STb) of porcine enterotoxigenic Escherichia coli elicit protective anti-LT and anti-STb antibodies. Clin. Vaccine Immunol. 2010, 17:1223-1231.
20. Zhang W., Zhang C., Francis D.H., Fang Y., Knudsen D., Nataro J.P., Robertson D.C. Genetic fusions of heat-labile (LT) and heat-stable (ST) toxoids of porcine enterotoxigenic Escherichia coli elicit neutralizing anti-LT and anti-STa antibodies. Infect. Immun. 2010, 78:316-325.
21. You J., Xu Y., He M., McAllister T.A., Thacker P.A., Li X., Wang T., Jin L. Protection of mice against enterotoxigenic E. coli by immunization with a polyvalent enterotoxin comprising a combination of LTB, STa, and STb. Appl. Microbiol. Biotechnol. 2011, 89:1885-1893.
22. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 2009, 98:1278-1316.
23. Hur J., Lee J.H. Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate. Clin. Vaccine Immunol. 2011, 18:203-209.
24. Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 2011, 18:546-551.
25. Zhang C., Zhang W. Escherichia coli K88ac fimbriae expressing heat-labile and heat-stable (STa) toxin epitopes elicit antibodies that neutralize cholera toxin and STa toxin and inhibit adherence of K88ac fimbrial E. coli. Clin. Vaccine Immunol. 2011, 17:1859-1867.
26. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008, 38:1404-1413.
27. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7:790-802.
28. Chadwick S., Kriegel C., Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 2010, 62:394-407.
29. Moseley S.L., Hardy J.W., Hug M.I., Echeverria P., Falkow S. Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of Escherichia coli. Infect. Immun. 1983, 39:1167-1174.
30. Dallas W.S., Gill D.M., Falkow S. Cistrons encoding Escherichia coli heat-labile toxin. J. Bacteriol. 1979, 139:850-858.
31. Zeng J., Deng G., Wang J., Zhou J., Liu X., Xie Q., Wang Y. Potential protective immunogenicity of recombinant Clostridium perfringens alpha-beta2-beta1 fusion toxin in mice, sows and cows. Vaccine 2011, 29:5459-5466.
32. Coester C., Nayyar P., Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur. J. Pharm. Biopharm. 2006, 62:306-314.
33. Coester C.J., Langer K., van Briesen H., Kreuter J. Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake. J. Microencapsul. 2000, 17:187-193.
34. Bhavsar M.D., Amiji M.M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. PharmSciTech 2008, 9:288-294.
35. Kuroiwa Y., Kasinathan P., Sathiyaseelan T., Jiao J.A., Matsushita H., Sathiyaseelan J., Wu H., Mellquist J., Hammitt M., Koster J., other 4 authors Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat. Biotechnol. 2009, 27:173-181.
36. Giannella R.A. Suckling mouse model for detection of heat-stable Escherichia coli enterotoxin: characteristics of the model. Infect. Immun. 1976, 14:95-99.
37. Yang, X., Thornburg, T., Holderness, K., Suo, Z., Cao, L., Lim, T., Avci, R., and Pascual, D. W.: Serum antibodies protect against intraperitoneal challengewith enterotoxigenic Escherichia coli, J. Biomed. Biotechnol., 2011, 632396 (2011).
38. Boedeker E.C. Vaccines for enterotoxigenic Escherichia coli: current status. Curr. Opin. Gastroenterol. 2005, 21:15-19.
39. Vauthier C., Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 2009, 26:1025-1058.
40. Cruz L.J., Tacken P.J., Bonetto F., Buschow S.I., Croes H.J., Wijers M., de Vries I.J., Figdor C.G. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol. Pharm. 2011, 8:520-531.
41. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25:1159-1164.
42. Ogawa Y., Yamamoto M., Okada H., Yashiki T., Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull. (Tokyo) 1988, 36:1095-1103.
43. Maurer P.H. II. Antigenicity of gelatin in rabbits and other species. J. Exp. Med. 1954, 100:515-523.
44. Schwick H.G., Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl. Haematol. 1969, 33:111-125.
45. Ikada Y., Tabata Y. Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 1998, 31:287-301.
46. Kuijpers A.J., Engbers G.H., Krijgsveld J., Zaat S.A., Dankert J., Feijen J. Cross-linking and characterisation of gelatin matrices for biomedical applications. J. Biomater. Sci. Polym. Ed. 2000, 11:225-243.
47. Ziv O., Avtalion R.R., Margel S. Immunogenicity of bioactive magnetic nanoparticles: natural and acquired antibodies. J. Biomed. Mater. Res. A 2008, 85:1011-1021.
48. Liang S., Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Invest. 2010, 39:449-467.